More efficient models are needed to assess potential carcinogenicity hazard of environmental chemicals based on early events in tumorigenesis. Here, we investigated time course profiles for key events in an established cancer mode of action. Using a case study approach, we evaluated two reference phthalates, di(2-ethylhexyl) phthalate (DEHP) and its stereoisomer di-n-octyl phthalate (DNOP), across the span of a two-year carcinogenicity bioassay. Male B6C3F1 mice received diets with no phthalate added (control), DEHP at 0.12, 0.60, or 1.20%, or DNOP at 0.10, 0.50, or 1.00% (n = 80-83/group) for up to 104 weeks with six interim evaluations starting at week 4. Mean phthalate doses were 139, 845, and 3147 mg/kg/day for DEHP and 113, 755, and 1281 mg/kg/day for DNOP groups, respectively. Incidence and number of hepatocellular tumors (adenoma and/or carcinoma) were greater at ≥ 60 weeks for all DEHP groups with time and dose trends, whereas DNOP had no significant effects. Key events supported a peroxisome proliferator-activated receptor alpha (PPAR␣) mode of action for DEHP, with secondary cytotoxicity at the high dose, whereas DNOP induced modest increases in PPAR␣ activity without proliferative or cytotoxic effects. Threshold estimates for later tumorigenic effects were identified at week 4 for relative liver weight (+24%) and PPAR␣ activity (+79%) relative to the control group. Benchmark doses (BMDs) for these measures at week 4 clearly distinguished DEHP and DNOP and showed strong concordance with values at later time points and tumorigenic BMDs. Other target sites included testis and kidney, which showed degenerative changes at higher doses of DEHP but not DNOP. Our results highlight marked differences in the chronic toxicity profiles of structurally similar phthalates and demonstrate quantitative relationships between early bioindicators and later tumor outcomes.
The two-year rodent carcinogenicity bioassay has been used for decades as the global standard for identifying chemicals with carcinogenic potential in humans (Huff, 1999) . However, the enormous resource and time requirements of this assay make it unfeasible as a tool to screen and evaluate the large numbers of chemicals currently in production. This limitation has led to repeated efforts to identify alternative shorter-term models or data types predictive of two-year bioassay outcomes (e.g., Elcombe et al., 2002; Sistare et al., 2011; Tennant et al., 1995) . Increased understanding of cellular targets and pathways leading to chemical-induced carcinogenesis has advanced these efforts, but quantitative predictive models using short-term data are still lacking. Such models would support chemical screening and prioritization, reduce the number of animals used in long-term testing, and allow for better allocation of resources to chemicals with the greatest potential human health risk.
The mode of action (MOA) framework has served as a cornerstone of risk assessment for environmental chemicals with positive tumor outcomes in the rodent bioassay (e.g., Boobis et al., 2006) . This framework provides the scaffold for organizing and evaluating data used in the determination of biological thresholds and human relevance of tumor outcomes . Recently, coordinated efforts have been initiated by a number of agencies that regulate chemicals to better define networks of health effects through the adverse outcome pathway (AOP) construct, which expands upon the traditional MOA framework (Ankley et al., 2010 ). An AOP is defined as a series of requisite mechanistically linked key events leading from a molecular initiating event to an adverse health outcome at the level of an individual or population. A fundamental part of the AOP concept is the predictive relationship between key events, which allows for prospective models to be generated, tested, and ultimately used in risk assessment and regulatory decision support.
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Temporal and dose concordance among key events are central criteria of the MOA and AOP frameworks . More implicit is the idea that quantitative links between key events, once established, can provide predictive estimates between early effects and later-stage outcomes (Ankley et al., 2010) . To better understand the time course dynamics for key events in an established cancer MOA/AOP and to investigate related dose and effect thresholds, here we comprehensively evaluated two-year toxicity profiles for two phthalate ester stereoisomers. Phthalates are a structurally diverse class of chemicals widely used in a variety of industrial and consumer products and ubiquitous as complex mixtures throughout the environment (EPA, 2009 ). Structural differences in ester side chains give individual phthalates distinct chemical, physical, and biological properties (EPA, 2009 ). These differences in many cases prevent direct substitution between phthalates, highlighting the complexity in finding suitable alternatives that lack toxicity concerns. Currently, eight phthalates are listed in the management plan of the U.S. Environmental Protection Agency (EPA) based on their exposure and toxicity profiles (EPA, 2009) . Included in this list are di(2-ethylhexyl) phthalate (DEHP) and its stereoisomer, di-n-octyl phthalate (DNOP). DEHP is a plasticizer in polyvinyl chloride (PVC) products and one of the most prevalent environmental phthalates worldwide, whereas DNOP constitutes about 20% of some phthalate mixtures used in PVC products (Kavlock et al., 2002; Shelby, 2006) .
Concern over human phthalate exposure is based largely on toxicological effects observed in rodent studies, including an increased incidence of liver tumors (e.g., David et al., 1999; IARC, 2000; Kluwe et al., 1982) and male reproductive and developmental effects (David et al., 2000; Shelby, 2006) . Phthalates have been reported to induce liver tumors similar to peroxisome proliferator chemicals (PPCs), a large and diverse class of chemicals including herbicides, industrial solvents, and pharmaceutical agents. In rodent studies, PPCs elicit a classic set of responses in the liver, including increased peroxisomes, induction of fatty acid-oxidizing enzymes, and hepatocyte hypertrophy and proliferation (Klaunig et al., 2003) . Chronic exposure to many PPCs at doses sufficient to induce moderate to marked peroxisome proliferation in rodents also results in increased incidence of hepatocellular adenomas and carcinomas, most likely through a nongenotoxic mechanism (Corton et al., 2014; Doull et al., 1999) .
The liver is a primary toxicity target for many xenobiotic compounds and the most common site of tumor outcomes in mouse carcinogenicity studies (Gold et al., 2005) . Hepatocellular tumors often result from sustained activation of different receptor types, including peroxisome proliferator-activated receptor ␣ (PPAR␣) (Corton et al., 2014) . The PPAR␣ subtype plays a dominant role in mediating hepatic effects of xenobiotic PPCs (Klaunig et al., 2003) . Clear evidence that PPAR␣ is involved in the short-term effects of PPCs comes from experiments performed in PPAR␣-null mice, which do not exhibit the classic short-term effects of PPC exposure (Klaunig et al., 2003) . In more chronic studies, hypolipidemic PPCs have also been shown to increase liver tumors in wild-type but not in PPAR␣-null mice, further supporting the role of PPAR␣ in liver tumorigenesis (Klaunig et al., 2003) . This evidence has been used to define key events in a cancer MOA/AOP, which include PPAR␣ activation (and associated increases in liver weight and hypertrophy), cell proliferation, clonal expansion of preneoplastic foci, and hepatocellular tumors (e.g., Corton et al., 2014) .
Despite an extensive literature on the effects of phthalates and other PPCs, time course dynamics have not been evaluated across the span of a two-year bioassay. This type of approach allows for dose-response modeling and linkage of early or intermediate markers with more chronic outcomes. In addition, the current study provides initial bioassay and time course data for a reference weak PPAR␣ activator, DNOP, in comparison with DEHP. The primary goals of the present study were to evaluate MOA/AOP key events for these strong (DEHP) and weak (DNOP) receptor activators and identify dose and effect thresholds for later-stage effects. This information is intended to support modeling efforts related to chemical prioritization, receptor-mediated tumorigenicity, and identification of less hazardous phthalate alternatives.
MATERIALS AND METHODS
Study design and feed dosing. This study followed a parallel-arm design in which male B6C3F1 mice at 21-28 days of age were divided into the following treatment groups: control; 0.12, 0.60, or 1.20% DEHP; and 0.10, 0.50, or 1.00% DNOP (n = 80-83/group). All animal work was performed at Charles River Laboratories (CRL) Pathology Associates (PAI) under EPA contract. Mice were socially housed with ad libitum water and food, standard temperature and humidity conditions, and a 12-h light-dark cycle. Phthalates were given in the diet for up to 104 weeks with interim pathology evaluations at weeks 4, 15, 30, 35, 52, and 60-79 . Six animals from each group were scheduled for sacrifice at all interim time periods except for the 60-79 week cohort, which included 10 per group. Mice were fed a base diet of Purina Laboratory Chow no. 5001 incorporating specified doses of phthalates from Purina Mills Inc. (Richmond, IN) and maintained under standard good laboratory practice (GLP)-compliant conditions in an AAALAC-accredited animal facility at CRL. All procedures involving the use of animals were approved by the CRL and EPA Institutional Animal Care and Use Committees.
Animals were observed daily throughout the study for clinical signs of toxicity and monitored regularly for food intake and body weight (BW). Animals showing signs of morbidity were sacrificed early. Compared with the control group, survival was lower in the 1.20% DEHP group (log-rank p < 0.001) but not in the other treatment groups (Table 1 ; Supplementary fig. 1 ). Because of increased mortality in the 1.20% DEHP group, all remaining animals in the final cohort were scheduled for early sacrifice at week 90. Unscheduled deaths were evaluated on histopathology when tissues were available and nonautolytic (Table 1) . Histopathology in four of these cases was limited to liver tumor incidence/counts, leading to slight differences in the number of animals evaluated for neoplastic compared with non-neoplastic liver lesion incidence. For statistical purposes, unscheduled deaths with pathology from the final cohort that occurred in the 60-79 week period (n ≤ 3 per group) were included with the 80-104 week cohort.
The test chemicals DEHP (CAS 117-81-7; Sigma-Aldrich Chemicals, Milwaukee, WI) and DNOP (CAS 117-84-0; Kodak Laboratory & Research Products via Baxter Scientific Products, Obetz, OH) were administered daily by feed. Chemicals were analyzed by gas liquid chromatography (GLC) in ether with a DB-624 Megabore Column (J&W Scientific, Folsom, CA) and confirmed to be 99.6% (DEHP) and 96.7% (DNOP) pure with no detectable impurities. Feed was prepared by Purina Mills (Richmond, IN) every 10-14 days throughout the study and tested 12 times during the study and at study end. Concentrations of DEHP and DNOP in feed were measured by ultraviolet absorption against standard concentrations set by capillary GLC and analyzed with Nelson Analytical Chromatography Software (Cupertino, CA). Base diet concentrations of DEHP were measured at < 0.002%. Target doses of DEHP were based on the dose range of effects in prior long-term mouse and rat studies (David et al., 1999; Kluwe et al., 1982) , whereas target doses of DNOP were based on effects described in previous short-term rat studies, including liver weight, histology, PPAR␣ activity, and promotional effects on diethylnitrosamine-induced hepatic foci (described in DeAngelo et al., 1986; Kavlock et al. 2002) . Estimated human dose equivalents of 0.12, 0.60, and 1.20% DEHP diets in mice are 13, 65, and 130 mg/kg/day, respectively (Kluwe et al., 1982) . Mean daily phthalate doses based on mean food intake, BW, and measured feed concentrations were 139, 845, and 3147 mg/kg/day for DEHP and 113, 755, and 1281 mg/kg/day for DNOP groups, respectively (Table 1). The average food consumption (mg/kg BW/day) was determined by cage across biweekly 3-4 day sampling periods during the experiment. Average daily feed and dose consumption increased starting at about 46 weeks in the 1.20% DEHP group; values for other groups remained relatively stable throughout the experiment (Supplementary fig. 2 ). Dose increases in the 1.20% DEHP group were due to a combination of increased food intake per animal and lower BW.
Tissue collection and histopathology. Staff pathologists from CRL/PAI conducted a complete necropsy examination for gross abnormalities on all animals, including those that died prior to scheduled sacrifice. BWs and weights of the liver, kidneys, spleen, and testes were recorded, and these tissues were fixed in 10% phosphate-buffered formalin. In addition, all gross lesions observed by the pathologist at necropsy were described, measured, counted, dissected out, fixed, sectioned, and examined separately. Portions of liver were also snap-frozen in liquid nitrogen and stored at −80
• C for use in enzyme activity and gene expression assays.
Fixed tissues were trimmed and processed into paraffin blocks, sectioned at 6 m onto glass slides, and stained with hematoxylin and eosin (H&E) using standard histologic procedures. A minimum of six sections of liver including left lateral, caudate, and right medial lobes were evaluated via light microscopy by board-certified study and peer-review pathologists. Pathology findings were recorded on a computerized pathology data management system, including all changes resulting from peer review. Histopathologic diagnoses followed standard criteria and nomenclature for neoplastic and non-neoplastic lesions (Thoolen et al., 2010) . Severity of non-neoplastic lesions was qualitatively scored using a 0-4 scale (0 = absent, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe). Severity index was calculated as the average severity score per group for a given change. All pathology data, tabulations, and observations were recorded under GLP-compliant conditions.
Liver palmitoyl coenzyme A oxidase activity. Activity of cyanide-insensitive palmitoyl CoA oxidase (PCO) was determined as a surrogate of PPAR␣ activation. The PCO enzyme encoded by the acyl-coenzyme A oxidase 1 (Acox1) gene is the rate-limiting step in the peroxisome fatty acid ␤-oxidation pathway. Portions of frozen liver samples (∼0.2-0.3 gm) from the 4, 15, 30, 35, 52, and 60-79 week time points were homogenized at a 1:10 weight-to-volume ratio in a buffer containing 0.25 M sucrose, 5mM sodium EDTA, and 20mM Tris HCl at pH 7.4 and temperature of 5
• C. Activity of PCO was then measured as nmol of nicotinamide adenine dinucleotide (NAD) reduced/min/mg protein using a spectrophotometric method modified to include flavin adenine dinucleotide as described previously (DeAngelo et al., 1989) . Protein concentration of liver homogenates was determined using the Lowry protein assay with Miller modification.
Liver cell proliferation. Cell proliferation in the liver was determined via autoradiography following administration of 3 Hthymidine, which is incorporated into cells undergoing DNA replication. At the 4, 15, 35, 52, 60-79, and 80-104 week time points mini-osmotic pumps (Alzet Corp., Palo Alto, CA) were used to deliver a total of 200 Ci 3 H-thymidine (1 mCi/ml) (ICN Radiochemicals, Irvine, CA) subcutaneously to six animals per group 5 days prior to sacrifice, as described previously (Carter et al., 1995) . Analysis was performed on sections taken from the left liver lobe. Slides coated with Kodak NTB3 emulsion were stored at 4
• C in a desiccator for 8 weeks and counterstained with hematoxylin after development. A total of 1000 hepatocytes within areas not including proliferative lesions were counted per liver section using random numbers to select the setting of the mechanical stage (Carter et al., 1995) . Any proliferative lesions present were counted separately for reference. Positive cells were scored based on a grain count > e Tissues were evaluated by histopathology on early deaths when available; tissues with autolysis were excluded, resulting in slight differences in the number of cases examined for some tissue types.
6 per nucleus, and the labeling index (LI) representing the percent of S-phase hepatocytes was calculated from the number of labeled cells/1000 × 100 (Carter et al., 1995) .
Serum lactic dehydrogenase activity and hormone concentrations. Blood was collected from the inferior vena cava at necropsy, and serum was prepared and stored at −20
• C. Serum lactic dehydrogenase (LDH) activity was measured as an indicator of hepatocellular cytotoxicity using a commercially available kit and protocol from Sigma Chemical Co. (St. Louis, MO) that detects the rate of formation of reduced NAD from NADH+ by increased absorbance at 340 nm. Serum LDH activity is expressed in units equal to the amount of enzyme required to catalyze formation of 1M NAD per minute. Serum hormone concentrations were measured using commercially available radioimmunoassay kits for testosterone (Coat-a-Count Total Testosterone, Diagnostic Products Corporation, Los Angeles, CA) and corticosterone (Cambridge Medical Technology Corporation, Billerica, MA). Testosterone was measured at all time points as a potential mediator of testicular effects, whereas corticosterone was measured at interim time points as a stress indicator and activity marker of the hypothalamic-pituitaryadrenal axis, which may indirectly affect gonadal function. Immunoassay kits were based on competitive antibody binding of 125 I-labeled testosterone or corticosterone ligands.
Liver gene expression. Gene expression was measured in frozen liver samples to evaluate receptor activity profiles for DEHP and DNOP. Global mRNA profiles were evaluated by microarray and targeted quantitative gene expression analysis was evaluated using hybridization-based and reversetranscriptase real-time quantitative polymerase chain reaction (qPCR) methods at the 30-week time point. To isolate RNA, frozen liver tissue (∼20 mg) was homogenized in RNAzol RT (Molecular Research Center, Cincinnati, OH) using ceramic beads in the Precellys 24 homogenizer. Extracellular material and DNA were removed with a 4-bromoanisole phase separation step followed by an alcohol precipitation and wash. Total RNA was re-dissolved in nuclease-free water and further purified with a Qiagen RNeasy MinElute column protocol (Qiagen GmbH, Hilden, Germany).
Analysis of RNA integrity, hybridization, and generation of microarray data was performed in the EPA National Health and Environmental Effects Research Laboratory (NHEERL) Genomics Research Core. The quality of total RNA was confirmed using the total RNA Nano chip assay on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Concentrations of RNA samples were determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). For hybridization, the biotin-labeled cRNA was produced from 200 ng total RNA using the Illumina TotalPrep RNA Amplification kit. Total cRNA was then quantified and evaluated for quality using an RNA 6000 LabChip kit on an Agilent 2100 Bioanalyzer. Samples were hybridized onto the Illumina Mouse Ref-8 v2.0 Expression BeadChip (Illumina Inc., San Diego, CA). Following overnight hybridization at 58
• C, bead arrays were washed and stained as recommended by the manufacturer and then scanned using Illumina iScan control software (version 3.3.28) . Microarray data are publicly available on the National Center for Biotechnology Information Gene Expression Omnibus database (accession no. GSE53523).
Expression of mRNA transcripts for target genes related to hepatocyte receptor activation and proliferation were measured in 30-week control and high-dose group liver samples using the hybridization-based Quantigene platform (no. 95051, Affymetrix, Santa Clara, CA). Preselected target genes included known activity markers of hepatocyte receptors aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane X receptor (PXR), and PPAR␣. A custom mouse panel Plex bead set was used to evaluate cytochrome p450 (Cyp) 1a1 (Cyp1a1) and Cyp1b1 for AhR, Cyp2b10 and Akr1b7 for CAR/PXR, pyruvate dehydrogenase kinase isoenzyme 4 (Pdk4) and Cyp4a10 for PPAR␣, and Mki67 for proliferation. Reference housekeeping genes (PpiB and Hprt) were used to normalize target genes. Briefly, 20-30 mg of frozen mouse liver tissue was bead homogenized in 800 ul of the Quantigene homogenizing solution and 8 ul of proteinase K solution (50 g/l stock) using a Precellys 24 homogenizer (5500 rpm for 20 s). Homogenate was placed at 65
• C for 30 min and vortexed at 10 min intervals throughout the incubation. Vials were spun at 16,000 × g for 15 min, and the supernatant was transferred to a new tube and centrifuged a second time. The assay was then performed based on kit instructions for the QuantiGene 2.0 Plex Assay with Affymetrix magnetic plate washer. Samples were diluted at a 1:4 ratio with homogenizing solution and incubated with capture beads and probe set overnight alongside universal mouse RNA curve standards. Following signal amplification and probe labeling, the signal was read as mean fluorescence intensity on a Luminex 100 (Luminex Corp., Austin, TX). All assay parameters and conditions were set as directed in the user manual, and temperature was validated using the QuantiGene incubator temperature validation kit.
Expression of mRNA transcripts for select target genes was also measured across all dose groups at 30 weeks by qPCR using the Applied Biosystems (ABI) TaqMan platform, based on methods described previously (Abbott et al., 2012) . Genes included Cyp1a1 for AhR, Cyp2b10 and Cyp3a11 for CAR/PXR, and Pdk4 for PPAR␣. Beta-2-microglobulin (B2m, Entrez no. 12010) was used as the endogenous reference gene based on uniform expression among all samples (< 0.5 standard deviation of cycle threshold, or C t ). The following TaqMan assays (ABI/Life Technologies, Foster City, CA) were used: Mm00487218 m1 for Cyp1a1, Mm00456591 m1 for Cyp2b10, Mm00731567 m1 for Cyp3a11, Mm01166879 m1 for Pdk4, and Mm00437762 m1 for B2m. Total RNA (2 g) was digested using 2 units of DNaseI (no. M6101, Promega Corp., Madison, WI) for 30 min at 37
• C followed by 10 min at 65
• C in a buffer containing 40 mM Tris (pH 8.0), 10 mM MgSO 4 , and 1 mM CaCl 2 . The RNA was then quantified using a Quant-iT RiboGreen RNA assay kit (no. R11490, Invitrogen Corp., Carlsbad, CA), and ∼1.5 g of RNA was reverse-transcribed using a High Capacity cDNA Archive Kit (no. 4322171, ABI). Amplification was performed on an ABI 7900HT Fast Real-Time PCR System in duplicate using 25 ng cDNA and TaqMan Universal PCR Master Mix (no. 4304437, ABI) in a total reaction volume of 12 l.
Benchmark dose modeling. Benchmark dose (BMD) response modeling was conducted using EPA BMD software (version 2.4.0) to estimate the threshold dose at which key target organ effects were discernible above or below background (i.e., control) levels. Duration-specific mean estimated DEHP or DNOP intake (mg/kg/day) served as the dose metric, and the central estimate (BMD) from the best-fitting model was used to compare low-dose potency between DEHP and DNOP and to examine the time course for progression of dose-related effects. The response at one control standard deviation was used to define continuous benchmark responses (BMD 1SD ) such as mean relative liver or testis weight and liver PCO activity and cell proliferation. For quantal histopathology endpoints in the kidney and liver, the 10% benchmark dose (BMD 10 ) was estimated. Thus, BMD 10 values were not estimated for quantal endpoints with a rate < 10% at the high dose group, which occurred at some of the interim time points. The five factors collectively taken into consideration for selecting the best-fit model included the global goodness-of-fit p value (minimum of 0.1 but highest value preferred), visual fit, Akaike Information Criterion (lowest value), Chi 2 residual values (< 2.0 at each dose level), and the margin between the BMD and its 95 th percentile lower confidence limit (BMDL) (EPA, 2012) . Given the correlation between the maximum tolerated dose (MTD) and carcinogenic potency (Krewski et al., 1993) , BMD modeling was performed with and without the 1.20% DEHP dose; exclusion of this group was justified by signs of excess general toxicity including mean BW loss of > 10%, increased mortality, and evidence of liver cytotoxicity not seen in other treatment groups. Further, BMD values for hepatocellular tumors were estimated based on the mortality-adjusted sample size using the poly-3 test to account for differential survival between treatment groups (Portier and Bailer, 1989) .
Statistical analyses. Primary study data were analyzed using SAS (SAS Institute Inc., Cary, NC) and SPSS (SPSS Inc., Chicago, IL) statistical programs. Pathology incidence data were analyzed by comparing results for each treatment group to the control group using a one-sided Fisher's exact test to test the hypothesis that there would be an increased incidence in one or more of the treated groups. For liver tumor incidence, each DEHP group was also compared with the corresponding DNOP dose group using a two-sided Fisher's exact test. Pairwise pvalues for all incidence data were adjusted using a Bonferroni multiple test correction for the number of direct comparisons, and an adjusted ␣ level of 0.05 was used to determine significance. A Cochran-Armitage trend test with Bonferroni adjustment was used to evaluate dose response trends for incidence of histopathology outcomes. Severity scores of non-neoplastic histopathology outcomes are presented only as descriptive data.
Continuous variables were screened for normality and homogeneity of variance. If these conditions were met, group differences for nongene expression data were evaluated using classical analysis of variance (ANOVA) and Tukey's multiple comparison procedure with an ␣ level of 0.05. Nonparametric data were evaluated by Kruskal-Wallis ANOVA followed by Wilcoxon rank sum pairwise tests between each treatment group and the control group. A linear test for trend was used for continuous parametric variables, whereas a Jonckheere trend test was used for nonparametric continuous data. Simple linear regression analysis was used to evaluate correlation of key early events with tumor incidence in the liver. A Bonferroni correction was used for nonparametric pairwise comparisons, trend tests, and regression analyses, and an adjusted ␣ level of 0.05 was used to determine significance. Continuous data values are reported as mean ± standard error unless otherwise stated.
Mortality was analyzed in SAS using the LIFETEST procedure to generate Kaplan-Meier survival distributions followed by pairwise testing of homogeneity between survival curves. Scheduled sacrifices were right-censored across time. Mortality was significantly higher only for the 1.20% DEHP group compared with the control group (log-rank p < 0.001) (Supplementary fig. 1 ). Univariate and adjusted (forward stepwise) Chi-Square tests did not show a significant association between early mortality and liver tumor status (adenoma or carcinoma).
For microarray data, raw intensity values were analyzed by Illumina GenomeStudio Data Analysis Software to assess data quality and apply quantile normalization. Principal component analysis (PCA) and visualization was conducted in TIGR Multiple Experiment Viewer Suite (TMEV v8; http://www.tm4.org/ mev) using all samples with no gene filter. Differentially expressed genes were examined using pairwise rank products procedures (Breitling et al., 2004) implemented in TMEV with a two-group design (control vs. treated) and Benjamini and Hochberg false discovery correction. Calculated fold change ratios were uploaded into Ingenuity Pathways Knowledgebase and DAVID Bioinformatics Database v6.7 (http://david.abcc. ncifcrf.gov/home.jsp) with a significance ␣ level set at ≤ 0.05.
For Quantigene expression data, individual well median values were averaged for each sample, corrected for background, and normalized based on the geometric mean of the two reference genes. Differences between treatment groups were determined using a Mann-Whitney ranked sum test for pairwise comparisons. For qPCR data, target gene expression was normalized by subtraction of the reference gene cycle threshold (C t ) from the target gene C t to generate delta Ct ( C t ) values for each individual (averaged across two technical replicates per RNA sample). Mean C t values were then calculated by subtracting the Ct value for each treatment group from the control group Ct. Extremely high C t values (> 40) were considered to represent undetectable gene expression. Differences between treatment groups were determined using ANOVA with Bonferroni's post hoc test applied for pairwise comparisons. Data were graphed and expressed as 2 − Ct (Abbott et al., 2012) . Biostatistical and bioinformatics support was provided by the EPA NHEERL Biostatistics and Bioinformatics Research Core.
RESULTS

DEHP and DNOP Elicit Distinct Effects on Liver
Tumorigenesis Liver tumor incidence and number. The only treatmentrelated tumor outcome was observed in the liver (Supplementary tables 1-3). Total incidence and number of hepatocellular tumors at ≥ 60 weeks were significantly increased for DEHP at all doses compared with the control group, whereas no significant effects were observed for DNOP at any dose (Table  2) . Dose trends for DEHP were also present for incidence and number of hepatocellular adenomas, carcinomas, and combined adenomas and/or carcinomas. The 1.20% DEHP group had the highest combined tumor incidence and number, showing a marked increase starting at 79 weeks (Supplementary figs. 3A and B). The incidence of carcinomas alone or combined with adenomas at ≥ 60 weeks differed between DEHP and DNOP only at the highest dose level, whereas the number of combined carcinomas and adenomas per individual was higher for DEHP compared with DNOP at all dose levels (Table 2) . Incidence and number of adenomas did not differ between DEHP and DNOP at any dose. Adenomas were initially observed at an earlier time point (30 weeks) than carcinomas (60 weeks) and were more likely to occur before study end compared with carcinomas (Supplementary figs. 3C-F). Histologically, carcinomas were more infiltrative than expansile with greater cellular pleomorphism (Supplementary figs. 4A and B) . The other most common tumor types observed were lymphosarcoma, hemangiosarcoma, and pulmonary alveolar-bronchiolar tumors; no group differences in incidence were observed for these neoplasms, which were considered to be incidental (Supplementary tables 1-3).
Key Events in the Liver Support a PPAR␣ MOA
Body and liver weight. Treatment effects of DEHP included lower BW and higher absolute and relative liver weights (Supplementary table 4). For BW, a significant trend was seen across DEHP dose groups at all time points measured. Effects were most prominent in the 1.20% DEHP group, which had significantly lower BW compared with the control group starting at 30 weeks. Effects of DNOP were limited to a dose trend for lower BW in the final time period. Liver weights were greater in all DEHP dose groups compared with the control group at all time points measured except week 35 for the 0.12% DEHP group; dose trends for DEHP were observed at all time points (Fig. 1A) . DNOP also resulted in higher liver weights but effects were less consistent and lower magnitude compared with DEHP. Relative liver weights were higher for the 0.50% and/or 1.00% DNOP Hepatocellular cytoplasmic alteration and cytomegaly. The earliest histopathologic effects in the liver were cytoplasmic alteration and hepatocytomegaly (hypertrophy). Cytoplasmic alteration was represented in the DEHP group by hepatocytes with abundant finely granular eosinophilic cytoplasm, typical of smooth endoplasmic reticulum (ER) and peroxisome proliferation in the rodent liver (Thoolen et al., 2010) (Supplementary  fig. 4C ). Exposure to DEHP resulted in increased incidence of cytoplasmic alteration at all doses and time points except 60-79 weeks and increased severity with dose (Fig. 1B) . Treatment with DNOP also resulted in increased incidence of cytoplasmic alteration at all doses at various time points; dose trends were observed at 15, 30, 52, and 80-104 weeks, but there was no clear increase in severity with dose. Compared with the DEHP groups, cytoplasmic alteration in the DNOP groups tended to be more amphophilic or basophilic, consistent with increased rough ER (Thoolen et al., 2010) . A related histopathologic change was hepatocellular cytomegaly, which was increased at the 0.60 and 1.20% DEHP doses starting at 15 weeks and at all DNOP doses at 80-104 weeks (Fig. 1C) ; dose trends were observed for DEHP but not DNOP.
Liver PCO activity. Liver PCO activity was measured as an indicator of PPAR␣ activation. Treatment with DEHP resulted in significantly higher PCO activity at all doses and time points except weeks 4 and 30 for the 0.12% DEHP dose; dose trends for DEHP were observed at all time points measured (Fig. 1D) . Treatment with DNOP also resulted in higher PCO activity for the 0.60 and 1.00% doses at all time points ≥ 35 weeks and the 0.12% dose at week 52; dose trends were observed at all time points measured after 4 weeks (Fig. 1D) . However, across all time points, the relative change in PCO activity from control for DNOP (+0.4-fold) was markedly less than for DEHP (+11.7-fold).
Liver mRNA profiles. Gene expression in the liver was evaluated at 30 weeks to evaluate transcriptional markers for activation of PPAR␣ and other receptors. The high doses of DEHP and DNOP showed distinct global gene expression profiles on microarray analysis, with discrete clustering of groups on PCA (Supplementary fig. 5A ). Significantly altered genes mapped to cell growth and proliferation and cell death biofunctions and proliferation, hyperplasia, and hepatocellular carcinoma toxicity functions for DEHP but not DNOP. Enriched paths for DNOP included cell energetics, protein synthesis and degradation biofunctions and liver steatosis, glutathione depletion, and fibrosis toxicity functions.
No increase in expression of gene markers for AhR or CAR/PXR was observed for DEHP or DNOP, whereas select PPAR␣ responsive genes were increased by DEHP and in some cases DNOP (Supplementary fig. 5B ). The most prominent preselected PPAR␣ response genes induced by DEHP on Illumina microarray were Cyp4a14 and Pdk4, whereas other markers of PPAR␣ activity such as Cyp4a10 and Acox1, Acox2, and Acox3 were either not detected or not significantly altered by DEHP. Targeted quantitative gene expression analysis showed a similar receptor profile, with significant induction of PPAR␣ markers Cyp4a10 and Pdk4 by DEHP (primarily at 0.60 and 1.20% doses), modest induction of Cyp4a10 but not Pdk4 by DNOP, and no effects of DEHP or DNOP on AhR or CAR/PXR markers (Supplementary figs. 5C and D) . Increased expression of the proliferation marker Mki67 was also observed for the high dose of DEHP but not DNOP (Supplementary fig. 5C ).
Liver cell proliferation and preneoplastic foci. Hepatocellular proliferation was increased at all time points measured for the 1.20% DEHP dose, with a marked increase at ≥ 30 weeks (Fig. 1E) . The 0.60% DEHP dose group also had greater proliferation compared with control but reached significance only at 4 weeks. For DNOP, dose trends in proliferation were noted at 35 weeks but no consistent group differences were observed. A similar pattern was seen for incidence of mitotic alteration, which was increased on histology at weeks 30, 35, 60-79, and 80-104 only in the 1.20% DEHP group (Supplementary table 5). Non-neoplastic proliferative lesions of hepatocytes included foci of cellular alteration, which are potential precursors to hepatocellular tumors (Thoolen et al., 2010) . Incidence of foci (combined types) was noted only in the 1.20% DEHP group at ≥ 60 weeks (Fig. 1F) .
Liver cytotoxicity. Clear evidence of direct liver cytotoxicity was limited to the 1.20% DEHP group. Effects on histopathology included hepatic necrosis, inflammation, oval cell hyperplasia, and/or pigment deposition at ≥ 30 weeks ( Figs. 2A and B ; Supplementary figs. 6A-C; Supplementary table 5). Pigment was present within both macrophages and hepatocytes and interpreted as lipofuscin or a related degradation byproduct. Oval cell proliferation was consistent with a response to sustained hepatotoxicity (Thoolen et al., 2010) . A dose trend for higher serum LDH was observed at weeks 4, 15, and 35 for DEHP ( Figs. 2A and B) . The timing of cytotoxicity changes on histology corresponds with the marked increases in hepatocellular proliferation in the 1.20% DEHP dose observed at ≥ 35 weeks, compatible with a regenerative response. Treatment with DNOP had no consistent effect on indicators of liver cytotoxicity.
Short-Term Effects are Highly Predictive of Liver
Tumorigenesis Correlation between early key events and tumor incidence. Early indicators of potential liver tumor effects include relative liver weight, enzyme activity, and cell proliferation (e.g., Allen et al., 2004; Boobis et al., 2009; Elcombe et al., 2002; Holsapple et al., 2006) . Here, we determined the correlation of these indicators with tumor incidence at different time points through- out the study. Relative liver weight and PCO activity at all time points through 79 weeks were strongly correlated with final tumor incidence (adenoma or carcinoma at ≥ 60 weeks) (R 2 > 0.8 and p < 0.05 for all) (Figs. 3A and B) . The strongest correlations were observed at 4 weeks (R 2 ≥ 0.87 for both). In contrast, cell proliferation at 4 weeks was highly correlated with final tumor incidence (R 2 = 0.96 and p < 0.001) but not at later time points (Supplementary fig. 7 ). Regression plots at 4 weeks indicated threshold values of 8% liver to BW (+26% vs. control), 7.5 nm/min/mg for PCO activity (+113% vs. control), and 0.81% proliferation LI (+268% vs. control) at the combined tumor incidence (63%) for the DEHP low effect level (0.12% dose). At the extrapolated threshold tumor incidence (53%) required for a significant difference from control for either phthalate (≥ 60 weeks), threshold values were 7% liver to BW (+24% vs. control), 6.3 nm/min/mg for PCO activity (+79% vs. control), and 0.63% for proliferation LI (+186% vs. control) at 4 weeks (Figs. 3A and B) . Threshold values for relative liver weight and PCO activity were similar to other time points, which showed an overall range of 6-7% and 5.0-6.8 nm/min/mg, respectively. BMD modeling of liver effects. BMD levels were estimated to describe low-dose potency and examine the temporal concordance between early and late events. Among observed liver effects, increased relative liver weight and PCO activity were the most sensitive early indicators (Figs. 3C and D) . For DEHP, BMDs at 4 weeks for liver weight and PCO activity were similar to values at other time points through week 52, whereas the BMD for cell proliferation at 4 weeks was markedly lower than later time points. The aggregate BMD value for DEHP for liver weight, PCO activity, and proliferation at 4 weeks (72 mg/kg/day) was similar to the mortality-adjusted BMD for hepatocellular carcinoma (71 mg/kg/day) at study end, ∼2-fold higher than the mortality-adjusted BMD for combined hepatocellular adenoma and carcinoma (35 mg/kg/day) at study end, and ∼4-fold lower than the average DNOP BMD for these measures at 4 weeks (287 mg/kg/day).
Testis and Kidney are Other Target Organs for DEHP But Not
DNOP Degenerative effects in testis. Testis weight (absolute and/or relative) was lower for the 1.20% DEHP dose group compared with the control group for all time points measured. Dose trends for DEHP were also observed at all time points (Supplementary table 4; Fig. 4A ). The 0.60% DEHP dose resulted in lower absolute testis weight at 30, 35, 52, and 80-104 weeks, and lower relative testis weight at 80-104 weeks, whereas the 0.12% DEHP dose did not significantly alter testis weight at any time point. Compared with control group values, mean relative testis weights in the 1.20% DEHP dose group ranged from −14% at 4 weeks to −72% at 60-79 weeks. Treatment with DNOP did not result in a significant difference in testis weight at any dose or time point compared with control. The primary histopathologic effect of DEHP was degeneration of the seminiferous tubules, observed at ≥ 30 weeks for the 1.20% dose and ≥ 60 weeks for the 0.60% dose (Supplementary table 2; Fig. 4B ). Severity was generally marked for the 1.20% dose of DEHP and mild to moderate for the 0.60% dose. Degenerative changes included tubular atrophy with loss and/or necrosis of germinal epithelial cells (Fig. 4C) . BMD estimates for these effects tended to decrease with time of exposure starting at week 35 until the final time point, when an increased incidence of tubular degeneration within the control group (presumably age-related) inflated the BMD value (Fig. 3C) . A secondary effect of DEHP on the testis was minimal to mild interstitial cell hyperplasia observed at weeks 30-79 only at the 1.20% dose (Supplementary table 2) . No treatment-related effects of DNOP on the testis histology were observed. Serum testosterone concentrations were not consistently altered by DEHP or DNOP, whereas serum corticosterone was increased at several time points only in the 1.20% DEHP group (Supplementary figs. 8A and B).
Degenerative effects in kidney. The third target organ with treatment-related outcomes was kidney. Effects of DEHP in-
FIG. 3. Regression plots and BMDs for DEHP and DNOP effects. (A) and (B)
Time course trends in the relationship between hepatocellular (HC) tumor incidence (adenoma or carcinoma at ≥ 60 weeks) for control (Con), DEHP, and DNOP groups and key early events in the liver: relative liver weight (A) and PCO activity as a marker of PPAR␣ activation (B). Best-fit curves are shown only for significant correlations (regression p < 0.05). Horizontal dashed line indicates extrapolated threshold tumor incidence required for a significant difference from control for either phthalate (≥ 60 weeks). (C) and (D) BMD estimates for DEHP (C) and DNOP (D) effects in the liver, testis, and kidney across time. BMD models were run with and without the 1.20% DEHP dose; estimates shown in (C) excluded this group based on evidence of general toxicity and increased mortality not seen in other treatment groups (indicating exceedance of MTD). Missing BMD estimates are due to lack of data, lack of statistical significance, or unacceptable fit (p < 0.1 or BMD > high dose) due to lack of dose response.
cluded lower absolute and relative kidney weights at ≥ 52 weeks for the 1.20% dose and 80-104 weeks for the 0.60% dose (Supplementary table 2; Fig. 4D ). Histopathologic effects in the kidney included moderate to marked tubular degeneration with luminal casts, tubular regeneration, and glomerular degeneration at the 1.20% dose of DEHP (Supplementary table 2 ; Figs. 4E and F) . Similar changes were observed for the 0.60% dose of DEHP but with less severity and at later time points. BMD estimates for any degenerative renal effect did not show any clear pattern across time (Fig. 3C) . No treatment-related effects of DNOP on the kidney were detected (Supplementary table 2) .
DISCUSSION
The main goal of this study was to characterize chronological patterns for key events in an established cancer MOA/AOP. Using a case study approach, we evaluated phthalate ester stereoisomers with different PPAR␣ activity. Our findings showed clear differences in the chronic toxicity profiles of DEHP and DNOP, including increases in liver cancer and degenerative changes in the testis and kidney for DEHP but not DNOP. In the liver, quantitative differences in early key events easily distinguished these two compounds beginning at the earliest time point (4 weeks) and allowed for estimation ofthresholds for later tumorigenic effects based on relative liver weight and PPAR␣ activity. BMD estimates for these measures at week 4 also distinguished DEHP and DNOP and showed strong concordance with values at later time points and with tumorigenic BMDs. These findings support prioritization approaches for structurally related chemicals based on targeted short-term studies and analysis of specific toxicity pathways.
Prior studies have investigated short-term correlates of carcinogenicity (or lack of carcinogenicity) in rodent bioassays. These studies include both whole animal (e.g., Sistare et al., 2011) and tissue-specific approaches (e.g., Allen et al., 2004; Boobis et al., 2009; Elcombe et al., 2002) . In the liver, subchronic predictors of liver tumor outcomes have included increased liver weight, hypertrophy, and necrosis (e.g., Allen et al., 2004; Boobis et al., 2009) . Collectively, these indicators provide high sensitivity but low specificity; moreover, they are primarily qualitative (+/−) and do not capture quantita- tive pathway-based or kinetic information. A more targeted approach would apply effect and dose thresholds for early key events within candidate MOAs/AOPs, incorporating both morphologic and molecular in vivo indicators and, in the future, data from in vitro systems (e.g., Kleinstreuer et al., 2013) . The goal of these more comprehensive probabilistic models would be to exclude noncarcinogens or rodent-specific carcinogens (with MOAs not relevant to human cancer or exposure) and decrease reliance on two-year rodent bioassay data in risk assessment. Findings from this study support the idea that DEHP induces liver cancer through a PPAR␣-mediated MOA/AOP. Key events included increases in PPAR␣ activation (cytoplasmic alteration, PCO activity, and PPAR␣-responsive gene markers), liver weight and hypertrophy, cell proliferation, preneoplastic foci, and hepatocellular adenomas and carcinomas. These key events showed both time and dose concordance. This information supports a large body of evidence indicating that PPAR␣ is the primary mediator of DEHP tumorigenesis in the liver (Corton et al., 2014; Klaunig et al., 2003) . However, several studies have challenged this idea and proposed a role for alternative receptors such as CAR/PXR and AhR (e.g., Guyton et al., 2009) . This work includes a report by Ito et al. (2007) which found that chronic exposure to DEHP resulted in a low incidence of liver tumors in PPAR␣-null but not wild-type mice. Additional work in various in vitro and rodent models further indicated that DEHP and its metabolites may also activate CAR/PXR and AhR under certain conditions (e.g., Ren et al., 2010) . Here, we found no evidence of alternative receptor activity in gene expression data at the 30-week time point, indicating that the changes attributed to these receptors in earlier studies may be confined to more acute exposures and have little influence on DEHP carcinogenesis. A limitation of the current study was the lack of overlap in PPAR␣ activity between higher DNOP and lower DEHP doses, which would have provided greater specificity in the link between receptor activation and tumor outcomes.
An alternative or secondary tumorigenic MOA/AOP to receptor-mediated mitogenesis in the liver is cytotoxicity (Holsapple et al., 2006) . Here, we observed clear evidence of liver cytotoxicity but only at the 1.2% dose of DEHP. In contrast to PPAR␣ effects, this high dose effect was not clearly evident until ≥ 30 weeks. Key events in this MOA/AOP include liver cell necrosis, histopathologic responses to hepatocyte injury (e.g., oval cell hyperplasia, inflammation), and sustained hepatocyte proliferation, which increased markedly starting at week 35 (> 20-fold control values). We speculate that the relatively smaller increase in proliferation LI noted only at 4 weeks in DEHP groups at 0.12% (3-fold control values) and 0.60% (4-fold con-trol values) was remnant from a more acute burst of proliferation (typical of receptor-mediated mitogens in the liver).
The human health relevance of PPAR␣-mediated tumors in rodents has been evaluated by several health organizations. Following initial carcinogenesis studies, the EPA and International Agency for Research on Cancer (IARC) classified DEHP as a category 2B human carcinogen ("possibly carcinogenic to humans") (EPA, 1999; IARC, 1982) . Subsequently, PPAR␣ activation was identified as a key mediator of rodent liver tumor effects with limited activity in the human liver (e.g., Doull et al., 1999) . The PPAR␣ MOA was later cited as justification for a change in the listing status of DEHP by IARC as "not classifiable as to its carcinogenicity to humans" (Group 3) (IARC, 2000) . The new classification was supported by the lack of a DNA-reactive mechanism for rodent liver tumors and evidence for peroxisome proliferation and hepatocellular proliferation in rodent studies but not in nonhuman primate studies and human hepatocyte cultures exposed to DEHP. This decision was later reversed based on new data showing increased incidence of testicular interstitial (Leydig) cell tumors and pancreatic acinar cell tumors in response to different PPCs; the IARC working group concluded that the human relevance of the molecular events leading to these tumors in rats and mice cannot be ruled out, and DEHP was reclassified as a Group 2B carcinogen (Grosse et al., 2011) . Most recently, a work group reviewed all of the most recent data concerning the human relevance of the PPAR␣ MOA for liver tumors and concluded that this MOA is not relevant for humans (Corton et al., 2014) .
Both DEHP and DNOP are metabolized by esterases in gut and blood to primary metabolites, mono(2-ethylhexyl) phthalate (MEHP) and mono-n-octyl phthalate (MNOP), respectively. These monoesters mediate most if not all of the liver effects of the parent compounds in vivo and exhibit similar potencies for related effects in vitro, including activation of PPAR␣ (as well as other PPAR subtypes) (Bility et al., 2004) and induction of PCO activity in mouse or rat primary hepatocytes (Kamendulis et al., 2002) . Based only on these in vitro findings, DEHP and DNOP exposure would be predicted to induce similar hepatic effects in the mouse. The marked difference in observed in vivo effects could be due in part to pharmacokinetic differences related to gut or blood esterase metabolism, which may facilitate greater MEHP tissue levels relative to MNOP. Support for this idea comes from an earlier study that reported differences in intestinal metabolism of different phthalates, even among closely related congeners; in this report, DEHP was metabolized twice as fast as DNOP (summarized in Kluwe et al., 1982) . Such metabolic differences may also account, at least in part, for effects described in the testis and kidney.
Degenerative changes in the testis were observed at the two highest dose groups of DEHP. Dose trends were apparent as early as 4 weeks for lower testicular weight, whereas histologic changes were not observed until week 30. Molecular events associated with reproductive tract effects of phthalates are not well characterized. For DEHP, testicular toxicity has generally been considered to be only partially dependent on PPAR␣. For example, DEHP exposure in PPAR␣-null mice results in similar, though delayed, testicular effects compared with wild-type mice (Ward et al., 1998) . Developmental exposure studies indicate that phthalates may affect the male reproductive tract largely via decreased testosterone levels and secondarily by direct cytotoxicity to Sertoli and interstitial cells (e.g., Corton and Lapinskas, 2005; Shelby, 2006) . Phthalate effects on androgen steroidogenesis and catabolism in adult exposure studies are less clear (Corton and Lapinskas, 2005 ). In the current study, testosterone concentrations measured at multiple time points showed no clear changes due to DEHP exposure, suggesting a direct or androgen-independent mechanism for testicular effects. In contrast to DEHP, DNOP did not result in significant effects on the testis, consistent with prior assessments based on shorterterm data that indicated low concern for reproductive toxicity (Kavlock et al., 2002) .
Renal effects of DEHP included decreased weight and tubular degeneration in the 0.60 and 1.20% dose groups and glomerular degeneration in the 1.20% dose group observed at ≥ 35 weeks. No treatment-related effects of DNOP were observed in the kidney. DEHP findings are consistent with several prior studies describing dose-and time-dependent nephrotoxicity following chronic DEHP exposure in mice (e.g., David et al., 2000) . Degenerative renal effects of DEHP have also been reported in both wild-type and PPAR␣-null mice, with increased severity in wild-type animals (e.g., Ward et al., 1998) . The latter study and others indicate that DEHP-induced renal toxicity in rodents may be mediated in part by PPAR␣, but the exact mechanisms remain unclear.
Recently, a proposal to change the current guidance on rodent carcinogenicity testing of pharmaceuticals was submitted to different regulatory agencies (FDA, 2013) . Proposed changes involve submission of data from noncarcinogenicity studies that would justify whether or not a bioassay would influence the overall cancer risk assessment of a compound. Short-term data focused on specific cancer pathways and biomarkers would comprise an important component of this new paradigm. Findings from the current study provide an early step in the process of identifying dose and temporal threshold estimates of short-term effects that lead to carcinogenicity outcomes (or not). Within the context of a single study, we identified early events in an established MOA/AOP predictive of tumorigenic effects and BMD concordance between early and late time points and effects. Future work in this area should enable more accurate risk predictions of carcinogenicity based on short-term bioactivity profiles and better define criteria under which rodent carcinogenicity studies add value to human cancer risk assessment.
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